Trial reportNature communications2022
A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain.
Abstract readClinical Trial
In one paragraph
Trial report in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults.Nature communications · 2023Trial
- Surmounting Recalcitrant Airway Inflammatory Disorders With a Multi-Targeting Therapeutic Strategy by Tannic Acid-Modified CuInPExploration (Beijing, China) · 2026Article
- Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial.EClinicalMedicine · 2025Article
- Estimating cumulative infection rate of COVID-19 after adjusting the dynamic zero-COVID policy in China.Infectious Disease Modelling · 2025Article
- Article
- A Hidden Guardian: The Stability and Spectrum of Antibody-Dependent Cell-Mediated Cytotoxicity in COVID-19 Response in Chinese Adults.Vaccines · 2025Article
- Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates.Nature communications · 2024Article
- Transforming vaccinology.Cell · 2024Review
- Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1.Signal transduction and targeted therapy · 2024Article
- Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review.Medicina (Kaunas, Lithuania) · 2024Review
- Modeling of antibody responses to COVID-19 vaccination in patients with rheumatoid arthritis.Scientific reports · 2024Article
- Heterologous booster vaccination enhances antibody responses to SARS-CoV-2 by improving Tfh function and increasing B-cell clonotype SHM frequency.Frontiers in immunology · 2024Article
- Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccine.EBioMedicine · 2024Article
- Real-World Study: Hybrid Immunity against SARS-CoV-2 Influences the Antibody Levels and Persistency Lasting More than One Year.Vaccines · 2023Article
- Article
- Inactivated SARS-CoV-2 Vaccine Booster Against Omicron Infection Among Quarantined Close Contacts.JAMA network open · 2023Article
- Understanding factors affecting Chinese medical staff's fear of receiving the fourth dose of COVID-19 vaccine: A cross-sectional study in Taizhou.Human vaccines & immunotherapeutics · 2023Article
- Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SYS6006, as a fourth-dose booster following three doses of inactivated vaccines in healthy adults: an open-labeled Phase 1 trial.Life metabolism · 2023Article
- Non-spike and spike-specific memory T cell responses after the third dose of inactivated COVID-19 vaccine.Frontiers in immunology · 2023Article
- Antibody Response to COVID-19 Vaccines in Healthcare Workers: Which One is More Successful? Homologous or Heterologous?Sisli Etfal Hastanesi tip bulteni · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Ji Wang *Department of Endocrinology, The First Affiliated Hospital, Sun Yat-sen University, 510080, Guangzhou, People's Republic of China. wangj683@mail.sysu.edu.cn.ORCID 0000-0002-8631-3264
Caiguangxi Deng *Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, 510080, Guangzhou, People's Republic of China.
Ming Liu *Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, 510080, Guangzhou, People's Republic of China.
Yihao Liu *Clinical Trials Unit, The First Affiliated Hospital, Sun Yat-sen University, 510080, Guangzhou, People's Republic of China.
Liubing LiDepartment of Laboratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, 510080, Guangzhou, People's Republic of China.
Zhangping HuangInstitute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, 510080, Guangzhou, People's Republic of China.
Liru ShangInstitute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, 510080, Guangzhou, People's Republic of China.
Juan JiangInstitute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, 510080, Guangzhou, People's Republic of China.
Yongyong LiInstitute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, 510080, Guangzhou, People's Republic of China.
Ruohui MoClinical Trials Unit, The First Affiliated Hospital, Sun Yat-sen University, 510080, Guangzhou, People's Republic of China.
Hui ZhangInstitute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, 510080, Guangzhou, People's Republic of China.ORCID 0000-0001-9692-3026
Min LiuDepartment of Laboratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, 510080, Guangzhou, People's Republic of China.
Sui PengInstitute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, 510080, Guangzhou, People's Republic of China. pengsui@mail.sysu.edu.cn.ORCID 0000-0002-7399-2579
Haipeng XiaoDepartment of Endocrinology, The First Affiliated Hospital, Sun Yat-sen University, 510080, Guangzhou, People's Republic of China. xiaohp@mail.sysu.edu.cn.ORCID 0000-0002-4188-336X
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effectiveness of a 3
Indexed as
COVID-19Viral VaccinesAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesHumansImmunity, HumoralMembrane GlycoproteinsSARS-CoV-2Spike Glycoprotein, CoronavirusVaccines, InactivatedViral Envelope ProteinsAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesMembrane GlycoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, InactivatedViral Envelope ProteinsViral Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.